FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $8,119,847 | -48.6% | 804,742 | +14.1% | 0.00% | -50.0% |
| Q3 2022 | $15,799,364 | -9.6% | 705,014 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $17,470,247 | -19.3% | 705,014 | +26.2% | 0.01% | 0.0% |
| Q1 2022 | $21,658,008 | -53.1% | 558,628 | -29.2% | 0.01% | -44.4% |
| Q4 2021 | $46,191,000 | +2.0% | 789,454 | +3.4% | 0.01% | -10.0% |
| Q3 2021 | $45,272,000 | -28.3% | 763,829 | +5.0% | 0.01% | -28.6% |
| Q2 2021 | $63,145,000 | -6.6% | 727,557 | -11.3% | 0.01% | -6.7% |
| Q1 2021 | $67,642,000 | -11.5% | 820,405 | -2.4% | 0.02% | -16.7% |
| Q4 2020 | $76,446,000 | +118.9% | 840,713 | -3.8% | 0.02% | +100.0% |
| Q3 2020 | $34,930,000 | +1113.3% | 873,914 | +941.6% | 0.01% | +800.0% |
| Q2 2020 | $2,879,000 | – | 83,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |